Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 12/20 | 1.00 |
| ▸ | SPHK1 | Q9NYA1 | 12/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CETP | P11597 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | GMNN | O75496 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | CXCR5 | P32302 | 2/20 | 1.00 |
| ▸ | CCR6 | P51684 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | UBE2N | P61088 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sphingosine SCHEMBL6348073 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| Sphingosine SCHEMBL2306197 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| SCHEMBL14378962 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| Sphingosine SCHEMBL22911044 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| SCHEMBL22986843 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| SCHEMBL21428474 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| SCHEMBL22986939 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| SCHEMBL20819097 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| Sphingosine SCHEMBL21114357 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| Sphingosine SCHEMBL863110 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629421-B2 | Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2026-05-19 | — | — | US | disclosed |
| EP-4591884-A1 | LIPID COMPOUND FOR NUCLEIC ACID DELIVERY, AND RELATED USE AND MEDICAMENT COMPRISING SAME | Beijing Baishihekang Pharmaceutical Technology (Bsjpharma) Co., Ltd. (CN) | 2025-07-30 | — | — | EP | disclosed |
| US-11974969-B2 | Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2024-05-07 | — | — | US | disclosed |
| US-20240099993-A1 | ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| US-20210015767-A1 | ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2021-01-21 | — | — | US | disclosed |
| WO-2019185038-A1 | ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID | 中国医学科学院基础医学研究所 | 2019-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240099993-A1 | ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID | SPHK2, SPHK1, S1PR2 | SPHK2 1/4885SPHK1 2/4885MAPT 4275/4885 |
| US-12629421-B2 | Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid | S1PR2, S1PR3, S1PR1 | SPHK2 4/4885SPHK1 8/4885MAPT 4746/4885 |
| US-20210015767-A1 | ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID | SPHK2, SPHK1, S1PR2 | SPHK2 1/4885SPHK1 2/4885MAPT 4275/4885 |
| US-11974969-B2 | Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid | SPHK2, SPHK1, S1PR2 | SPHK2 1/4885SPHK1 2/4885MAPT 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.